Abstract
Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Keywords: Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Current Vascular Pharmacology
Title:Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis
Volume: 10 Issue: 6
Author(s): Marcello Arca, Giovanni Pigna and Carla Favoccia
Affiliation:
Keywords: Atherogenic dyslipidemia, VLDL secretion, apoB metabolism, insulin resistance
Abstract: Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
Export Options
About this article
Cite this article as:
Arca Marcello, Pigna Giovanni and Favoccia Carla, Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520864
DOI https://dx.doi.org/10.2174/157016112803520864 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Umbilical Cord Blood Cells and Diabetes Mellitus: Recent Advances
Current Stem Cell Research & Therapy Current Biology of MTP: Implications for Selective Inhibition
Current Topics in Medicinal Chemistry Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis
Current Diabetes Reviews N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain
Current Pharmaceutical Design Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities
Current Medicinal Chemistry Should Cushing's Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?
Current Vascular Pharmacology Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Pregnancy: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Angiotensin I-Converting Enzyme: A Pathogenetic Role in Diabetic Renal Damage?
Current Diabetes Reviews Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Current Vascular Pharmacology Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss
Current Neurovascular Research Epigenomic Approach in Understanding Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets p66 Shc as the Engine of Vascular Aging
Current Vascular Pharmacology Endothelial Extracellular Vesicles Produced by Senescent Cells: Pathophysiological Role in the Cardiovascular Disease Associated with all Types of Diabetes Mellitus
Current Vascular Pharmacology Mediterranean Food Pattern in Rheumatoid Arthritis
Current Rheumatology Reviews Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and New Therapeutic Interventions in Lipid-Related Cardiovascular Risk Factors)
Current Pharmaceutical Design Engineering Biomimetic Materials for Islet Transplantation
Current Diabetes Reviews iTRAQ-Based Proteomic Analysis of the Rat Pancreas Following Gastric Bypass Surgery
Current Proteomics